Periodo 2020-2024
Carretero Hernández G, Ara Martín M, Armesto Alonso S, Belinchón Romero I,
Eiris Salvado N, Ferrán Farrés M, Galache Osuna C, García Bustínduy M, García
Latasa de Araníbar J, Juliá Manresa M, Llamas Velasco M, López Ferrer A, Roncero
Riesco M, Ruiz Genao D, Ruíz-Villaverde R, Salgado Boquete L, Soria Martínez C,
Vilarrasa Rull E, Descalzo MA; AEDV Psoriasis Group. [Translated article]
Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A
National Cross-Sectional Study. Actas Dermosifiliogr. 2024 Oct
9:S0001-7310(24)00766-X. English, Spanish. doi: 10.1016/j.ad.2024.10.009. Epub
ahead of print. PMID: 39389350.
Ceravalls J, Ruiz-Villaverde R, Armesto S, Fernández-Armenteros JM, Riera-
Monroig J, Gracia-Cazaña T, Quintana-Codina M, Iglesias-Sancho M, Salleras M,
Moya AI, Melgosa Ramos FJ, Ferran M. Anti-IL-23 therapy for the treatment of
moderate-to-severe inverse psoriasis: A 52-week multicentre study. J Eur Acad
Dermatol Venereol. 2024 Sep 13. doi: 10.1111/jdv.20346. Epub ahead of print.
PMID: 39269142.
Butrón-Bris B, Llamas-Velasco M, Ovejero-Benito MC, Santos-Juanes J,
Martínez-López A, Ruiz-Villaverde R, Roustan G, Baniandrés O, Izu-Belloso R, de
la Cueva P, Sahuquillo-Torralba A, Gónzalez-Quesada A, Vilarrasa-Rull E, Pujol-
Montcusí J, García-Martínez J, Navares M, Palomar-Moreno I, Novalbos J, Abad-
Santos F, Daudén E, de la Fuente H. Genetic polymorphisms to identify patients
with an optimal response to tildrakizumab in psoriasis patients from real-life
clinical practice. Exp Dermatol. 2024 Aug;33(8):e15152. doi: 10.1111/exd.15152.
PMID: 39081053; PMCID: PMC11605493.
Puig L, Izu Belloso R, Rivera-Díaz R, Mollet Sánchez J, Rodríguez Fernández-
Freire L, Sahuquillo-Torralba A, Ruiz-Villaverde R; IMPULSE investigators group.
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics,
Clinical Characteristics, and Management of Generalized Pustular Psoriasis
Patients in Spain: IMPULSE Study. Dermatology. 2024 Jul 17:1-15. doi:
10.1159/000540019. Epub ahead of print. PMID: 39019021.
Daudén E, Belinchón I, Colominas-González E, Coto P, de la Cueva P, Gallardo
F, Poveda JL, Ramírez E, Ros S, Ruíz-Villaverde R, Comellas M, Lizán L. Defining
well-being in psoriasis: A Delphi consensus among healthcare professionals and
patients. Sci Rep. 2024 Jun 24;14(1):14519. doi: 10.1038/s41598-024-64738-6.
PMID: 38914574; PMCID: PMC11196587.
Carretero Hernández G, Ara Martín M, Armesto Alonso S, Belinchón Romero I,
Eiris Salvado N, Ferrán Farrés M, Galache Osuna C, García Bustínduy M, García
Latasa de Araníbar J, Juliá Manresa M, Llamas Velasco M, López Ferrer A, Roncero
Riesco M, Ruiz Genao D, Ruíz-Villaverde R, Salgado Boquete L, Soria Martínez C,
Vilarrasa Rull E, Descalzo MA; en representación del Grupo de Psoriasis de la
AEDV. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain:
A National Cross-Sectional Study. Actas Dermosifiliogr. 2024 Jun
12:S0001-7310(24)00507-6. English, Spanish. doi: 10.1016/j.ad.2024.05.022. Epub
ahead of print. PMID: 38876209.
Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, Llamas-Velasco M, Rull
EV, Ruiz Villaverde R, Ferran M, Pitarch G, Lopez A, Beltran E, Urruticoechea-
Arana A, Riera-Monroig J, Alsina M, Vidal D, Belinchón Romero I, Notario J,
Carrascosa JM, Gonzalez-Delgado V, Mollet J, Ribera M, Gallardo F. Certolizumab
pegol effectiveness, survival and safety in patients with psoriasis: A
multicenter retrospective analysis in daily clinical practice by the Spanish
Psoriasis Group. Int J Dermatol. 2024 Dec;63(12):1720-1727. doi:
10.1111/ijd.17238. Epub 2024 May 12. PMID: 38736107.
8: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Cebolla-Verdugo M, Prados-
Carmona A, Hernández-Montoya C, Armario-Hita JC, Galán-Gutiérrez M. Bimekizumab:
Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia,
Spain. Life (Basel). 2024 Feb 20;14(3):281. doi: 10.3390/life14030281. PMID:
38541607; PMCID: PMC10971645.
Martorell A, Santos-Alarcón S, Sahuquillo-Torralba A, Rivera-Díaz R,
Belinchón-Romero I, Ruiz-Genao D, Romero-Maté A, Ruiz-Villaverde R, Ferrán-
Farrés M, Gallardo-Hernández F, Almenara-Blasco M, Alonso-Suárez J, González-
Cantero Á, Martínez-Lorenzo E, Fernández-Armenteros JM, de Alcázar-Viladomiu E,
García-Latasa J, Rocamora-Durant V, Ara-Martín M, Mateu-Puchades A, Llamas-
Velasco M, Vilarrasa-Rull E, Velasco-Pastor M, De la Cueva P, Carrascosa JM,
Magdaleno-Tapial J. Real-world safety and efficacy of risankizumab in psoriatic
patients: a multicenter, retrospective, and not-interventional study. Actas
Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00187-X. English, Spanish. doi:
10.1016/j.ad.2024.02.030. Epub ahead of print. PMID: 38452889.
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A,
Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-
Carazo JL, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-
Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M,
Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P,
Abad-Santos F, Daudén-Tello E, de la Fuente H. Pharmacogenetic biomarkers for
secukinumab response in psoriasis patients in real-life clinical practice. J Eur
Acad Dermatol Venereol. 2023 Dec 28. doi: 10.1111/jdv.19782. Epub ahead of
print. PMID: 38153843.
Ruiz-Villaverde R, Galan-Gutierrez M, Armario-Hita JC, Rodriguez-Fernandez-
Freire L. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice
Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A
Retrospective Multicenter Study. Actas Dermosifiliogr. 2024 Mar;115(3):321-323.
English, Spanish. doi: 10.1016/j.ad.2023.10.023. Epub 2023 Nov 2. PMID:
37923077.
Prados-Carmona A, Ruiz-Villaverde R, Ruiz-Carrascosa JC. Rupioid psoriasis.
Semergen. 2023 Oct;49(7):102061. doi: 10.1016/j.semerg.2023.102061. Epub 2023
Sep 8. PMID: 37690349.
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R,
López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M,
Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar
E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-
Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la
Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group
of the Spanish Academy of Dermatology and Venereology. Effectiveness and safety
of tildrakizumab for the treatment of psoriasis in real-world settings at
24 weeks: A retrospective, observational, multicentre study by the Spanish
Psoriasis Group. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2517-2525. doi:
10.1111/jdv.19468. Epub 2023 Sep 1. PMID: 37625815.
Couselo-Rodríguez C, Batalla A, Carrascosa JM, Chicharro P, González-Quesada
A, de la Cueva P, Giménez-Arnau AM, Gilaberte Y, Rodríguez-Serna M, Montero-
Vilchez T, Ruiz-Villaverde R, Elosua-González M, Silvestre-Salvador JF, Munera-
Campos M, Sánchez-Pérez J, Carretero G, Mauleón-Fernández C, Curto-Barredo L,
Ballano-Ruiz A, Botella-Estrada R, Arias-Santiago S, Navarro-Triviño FJ,
Roustan-Gullón G, Betlloch I, Del Alcázar E, Abalde-Pintos MT, Suárez-Perez J,
García-Doval I, Descalzo MÁ, Flórez Á. Drug Survival in Cyclosporine Treatment
for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic
Dermatitis Registry (BIOBADATOP). Actas Dermosifiliogr. 2023 Jul
22:S0001-7310(23)00608-7. English, Spanish. doi: 10.1016/j.ad.2023.07.014. Epub
ahead of print. PMID: 37482292.
Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de
la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML,
Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén
Olasolo P. Family Planning Concerns Among Women With Psoriasis: A Descriptive,
Cross-Sectional, Multicenter Study. Actas Dermosifiliogr. 2024 Jan;115(1):10-20.
English, Spanish. doi: 10.1016/j.ad.2023.06.015. Epub 2023 Jul 11. PMID:
37442420.
Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M,
Rivera R, Carrascosa JM, de la Cueva-Dovao P, Armesto-Santos S, Ruíz-Villaverde
R, Velasco-Pastor M, Magdaleno-Tapial J, Yanguas-Bayona JI, Ribera-Pibernat M,
Salgado-Boquete L, Herranz-Pinto P, Romero-Mate A, Martínez-Lorenzo E, López-
Estebaranz JL, Ballescá-López F, Botella-Estrada R. Effectiveness and safety of
brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A
multicentre retrospective study in a Spanish population. Australas J Dermatol.
2023 Nov;64(4):e317-e326. doi: 10.1111/ajd.14130. Epub 2023 Jul 12. PMID:
37435962.
Ruiz-Villaverde R, Galán-Gutiérrez M, Llamas-Velasco M, Salgado-Boquete L,
Puig L, de la Cueva P, Carrascosa JM; en representación del Grupo Español de
Psoriasis (GPs). Updated Position of the Spanish Psoriasis Group (GPs) on the
Use of Biosimilar Drugs in Moderate to Severe Psoriasis. Actas Dermosifiliogr.
2023 Jun;114(6):494-501. English, Spanish. doi: 10.1016/j.ad.2023.02.016. Epub
2023 Mar 10. PMID: 36906260.
Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande
A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R,
Carrascosa JM; Grupo Multidisciplinar y Grupo de Consenso. Selection of Quality
Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi
Consensus Study. Actas Dermosifiliogr. 2023 Nov-Dec;114(10):865-883. English,
Spanish. doi: 10.1016/j.ad.2023.02.002. Epub 2023 Feb 15. PMID: 36796538.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Vasquez Chinchay F, Galán-Gutiérrez M. Effectiveness, survival and safety of
guselkumab attending to basal characteristics in moderate-to-severe psoriatic
patients: a cohort study. F1000Res. 2022 Oct 17;11:1178. doi:
10.12688/f1000research.122945.2. PMID: 36567685; PMCID: PMC9755754.
Galan-Gutierrez M, Font-Ugalde P, Padilla L, Hernandez-Montoya C, Godoy D,
Armario-Hita JC, Ruiz-Villaverde R. Brodalumab: Efficacy, safety, and survival
in mid-term (52 weeks) on real clinical practice in Andalucia, Spain. Int J
Dermatol. 2023 May;62(5):700-706. doi: 10.1111/ijd.16527. Epub 2022 Dec 10.
PMID: 36495585.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Pérez-Gil A, Font-Ugalde P,
Galán-Gutiérrez M. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term
(52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the
Therapeutic Goals of the Spanish Psoriatic Guidelines. Life (Basel). 2022 Nov
14;12(11):1883. doi: 10.3390/life12111883. PMID: 36431015; PMCID: PMC9697008.
Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, C
Armario-Hita J, Pérez-Gil A, Galán-Gutiérrez M. Super-Responders in Moderate-
Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future
Perspectives. Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.
PMID: 36143449; PMCID: PMC9505180.
Ruiz-Villaverde R, Chinchay FV, Rodriguez-Fernandez-Freire L, Armario-Hita
JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab dosing interval optimization in
adult patients with moderate-to-severe psoriasis switching from ustekinumab.
Dermatol Ther. 2022 Nov;35(11):e15835. doi: 10.1111/dth.15835. Epub 2022 Sep 23.
PMID: 36114755.
Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-
Gutierrez M. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks)
in Three Tertiary Hospitals in Andalucia (Spain). J Clin Med. 2022 Aug
30;11(17):5098. doi: 10.3390/jcm11175098. PMID: 36079026; PMCID: PMC9456674.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Chinchay FV, Galán-Gutiérrez M. Guselkumab as a switching strategy after
anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
Dermatol Ther. 2022 Oct;35(10):e15760. doi: 10.1111/dth.15760. Epub 2022 Aug 15.
PMID: 35971573.
Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC.
Switching from reference adalimumab to biosimilar. Assessment of clinical
outcomes in psoriasis. Int J Dermatol. 2023 Mar;62(3):e159-e161. doi:
10.1111/ijd.16399. Epub 2022 Aug 10. PMID: 35948826.
Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Julià M, Ruiz-Villaverde
R, Rodríguez Fernández-Freire L, Notario J, Llamas-Velasco M, Ferran M,
Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque
psoriasis at 52 weeks in a real-world clinical setting: observational,
retrospective, multi-centre study by the Spanish Psoriasis Group. J Dermatolog
Treat. 2022 Sep;33(6):2878-2880. doi: 10.1080/09546634.2022.2079596. Epub 2022
May 26. PMID: 35593480.
Navarro-Triviño FJ, Ruiz-Villaverde R. Allergic contact dermatitis in a
psoriasis patient caused by cetylstearyl alcohol. Contact Dermatitis. 2022
Sep;87(3):283-285. doi: 10.1111/cod.14136. Epub 2022 May 3. PMID: 35474578.
Cuenca-Barrales C, Ruiz-Carrascosa JC, Ruiz-Villaverde R. RF - Should Striae
be Considered a Predisposing Factor for Koebner Phenomenon in Psoriasis? Actas
Dermosifiliogr. 2022 Feb;113(2):190-191. English, Spanish. doi:
10.1016/j.ad.2020.04.016. Epub 2021 Sep 10. PMID: 35244565.
Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Ruiz-Villaverde R,
Llamas-Velasco MDM, Rocamora V, Julià M, Notario J, Fernández-Freire LR,
Sahuquillo-Torralba A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P,
Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of
psoriasis in real-world settings at 24 weeks: A retrospective, observational,
multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022
Feb;35(2):e15231. doi: 10.1111/dth.15231. Epub 2022 Jan 17. PMID: 34820971.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Galán-Gutiérrez M. Super responders to guselkumab treatment in moderate-to-
severe psoriasis: a real clinical practice pilot series. Int J Dermatol. 2022
Aug;61(8):1029-1033. doi: 10.1111/ijd.15784. Epub 2021 Nov 3. PMID: 34731493.
Galán-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R.
Tildrakizumab: short-term efficacy and safety in real clinical practice. Int J
Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840. Epub 2021 Oct 11.
PMID: 34632570.
Aguayo-Carreras P, Ruiz-Carrascosa JC, Ruiz-Villaverde R, Molina-Leyva A.
Four years stability of type D personality in patients with moderate to severe
psoriasis and its implications for psychological impairment. An Bras Dermatol.
2021 Sep-Oct;96(5):558-564. doi: 10.1016/j.abd.2021.02.005. Epub 2021 Jul 15.
PMID: 34274184; PMCID: PMC8441460.
Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la
Cueva P, Belinchón I. A New Classification of the Severity of Psoriasis: What's
Moderate Psoriasis? Life (Basel). 2021 Jun 29;11(7):627. doi:
10.3390/life11070627. PMID: 34209585; PMCID: PMC8307918.
Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R.
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A
Prospective, Observational, Non-Interventional, Single-Center Study of Patient
Adherence and Satisfaction in Daily Use. Dermatol Pract Concept. 2021 May
20;11(3):e2021056. doi: 10.5826/dpc.1103a56. PMID: 34123560; PMCID: PMC8172017.
Herranz P, Trasobares L, Mateu A, Martínez E, Ruiz-Villaverde R, Baniandrés
O, Mataix Díaz J, Jiménez-Gómez N, Serra M, Ruiz Genao DP, Rivera N, Tercedor-
Sánchez J, Garcia C, Cordey M, Herrera-Acosta E. Characterization and Outcomes
in Patients Treated With Apremilast in Routine Clinical Practice in Spain:
Results From the APPRECIATE Study. Actas Dermosifiliogr (Engl Ed). 2021 May
27:S0001-7310(21)00202-7. English, Spanish. doi: 10.1016/j.ad.2021.05.010. Epub
ahead of print. PMID: 34052202.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Galán-Gutiérrez M. Guselkumab: Mid-term effectiveness, drug survival, and
safety in real clinical practice. Dermatol Ther. 2021 Mar;34(2):e14798. doi:
10.1111/dth.14798. Epub 2021 Feb 7. PMID: 33484067.
Ruiz-Villaverde R, Ruiz-Carrascosa JC, Galán-Gutierrez M, Armario-Hita JC.
Risankizumab: A pilot study of short-term effectiveness and safety in real
clinical practice. Dermatol Ther. 2021 Jan;34(1):e14711. doi: 10.1111/dth.14711.
Epub 2021 Jan 6. PMID: 33368889.
Ruiz-Villaverde R, Rodríguez Fernández-Freire L, Galán-Gutiérrez M, Armario-
Hita JC, Martinez-Pilar L. Secukinumab: Drug Survival in Clinical Practice
Settings. Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):361-364. English,
Spanish. doi: 10.1016/j.ad.2019.05.018. Epub 2020 Oct 28. PMID: 33129781.
Navarro-Triviño FJ, Ruiz-Villaverde R. Successful treatment of erythematous-
squamous disorders of the external auditory canal with tacrolimus and
clotrimazole in otic oil: Our experience in 25 patients. Dermatol Ther. 2020
Nov;33(6):e14471. doi: 10.1111/dth.14471. Epub 2020 Nov 4. PMID: 33112026.
Belinchón I, Velasco M, Ara-Martín M, Armesto Alonso S, Baniandrés Rodríguez
O, Ferrándiz Pulido L, García-Bustinduy M, Martínez-López JA, Martínez Sánchez
N, Pérez Ferriols A, Pérez Pascual E, Rivera Díaz R, Ruiz-Villaverde R, Taberner
Ferrer R, Vicente Villa A, Carrascosa JM. Management of Psoriasis During
Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement.
Actas Dermosifiliogr (Engl Ed). 2021 Mar;112(3):225-241. English, Spanish. doi:
10.1016/j.ad.2020.10.002. Epub 2020 Oct 13. PMID: 33065101.
Rivera R, Velasco M, Vidal D, Carrascosa JM, Daudén E, Vilarrasa E, Notario
J, Ruíz-Villaverde R, Yanguas I, García-Latasa FJ, Ferrán M, Lázaro-Simó A, de
la Cueva P, Salgado-Boquete L, Belinchón I. The effectiveness and safety of
ixekizumab in psoriasis patients under clinical practice conditions: A Spanish
multicentre retrospective study. Dermatol Ther. 2020 Nov;33(6):e14066. doi:
10.1111/dth.14066. Epub 2020 Sep 3. PMID: 32713119.
Ruiz-Villaverde R, Galán-Gutierrez M. Biosimilars in psoriasis: what should
your positioning be? Expert Opin Biol Ther. 2021 Jan;21(1):81-86. doi:
10.1080/14712598.2020.1798924. Epub 2020 Jul 27. PMID: 32684012.
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E,
Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-
Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C,
Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet
J, Belinchón I, Carrascosa JM. Real-world effectiveness and safety of apremilast
in psoriasis at 52 weeks: a retrospective, observational, multicentre study by
the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2020
Dec;34(12):2821-2829. doi: 10.1111/jdv.16439. Epub 2020 Jun 17. PMID: 32271966.
Rodriguez Fernandez-Freire L, Galán-Gutierrez M, Armario-Hita JC, Perez-Gil
A, Ruiz-Villaverde R. Guselkumab: Short-term effectiveness and safety in real
clinical practice. Dermatol Ther. 2020 May;33(3):e13344. doi: 10.1111/dth.13344.
Epub 2020 Apr 20. PMID: 32227659.
Ruiz-Villaverde R, Galán-Gutierrez M, Carlos Armario-Hita J, Ruiz-Carrascosa
JC, Font-Ugalde P. Brodalumab: short-term effectiveness and safety in real
clinical practice. Int J Dermatol. 2020 Sep;59(9):e340-e341. doi:
10.1111/ijd.14866. Epub 2020 Mar 30. PMID: 32227476.
Ruiz-Villaverde R, Ayén-Rodriguez A, Llamas-Molina JM, Ruiz-Carrascosa JC.
Risankizumab as a promising therapeutic approach in obese patients. Dermatol
Ther. 2020 May;33(3):e13323. doi: 10.1111/dth.13323. Epub 2020 Apr 8. PMID:
32196833.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M, Armario-
HIta JC, Martinez-Pilar L. Drug survival, discontinuation rates, and safety
profile of secukinumab in real-world patients: a 152-week, multicenter,
retrospective study. Int J Dermatol. 2020 May;59(5):633-639. doi:
10.1111/ijd.14819. Epub 2020 Mar 15. PMID: 32173862.
Cañete JD, Nolla JM, Queiro R, Rodríguez MJ, Ruiz M, Lizán L; MERECES
Working Group. Expert Consensus on a Set of Outcomes to Assess the Effectiveness
of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. J Rheumatol.
2020 Nov 1;47(11):1637-1643. doi: 10.3899/jrheum.191056. Epub 2020 Feb 1. PMID:
32007930.
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M,
Martinez-Pilar L. Efficacy of secukinumab in psoriasis and psoriatic arthritis:
A retrospective multicentre study. Med Clin (Barc). 2020 May 8;154(9):370-371.
English, Spanish. doi: 10.1016/j.medcli.2018.12.009. Epub 2019 Feb 1. PMID:
30717997.